Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,832 shares of the medical equipment provider’s stock after selling 200 shares during the quarter. Daymark Wealth Partners LLC’s holdings in Zimmer Biomet were worth $623,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ZBH. Ameriprise Financial Inc. lifted its holdings in shares of Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after purchasing an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after purchasing an additional 1,488,918 shares during the last quarter. Nuveen LLC bought a new stake in shares of Zimmer Biomet in the 1st quarter worth approximately $155,891,000. Alyeska Investment Group L.P. bought a new stake in shares of Zimmer Biomet in the 1st quarter worth approximately $101,294,000. Finally, Dodge & Cox lifted its holdings in shares of Zimmer Biomet by 2.3% in the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after purchasing an additional 446,018 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Down 0.2%

Shares of Zimmer Biomet stock opened at $99.55 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a market capitalization of $19.72 billion, a P/E ratio of 24.22, a PEG ratio of 2.29 and a beta of 0.67. The business’s fifty day moving average price is $101.59 and its two-hundred day moving average price is $97.62. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the previous year, the business earned $2.01 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s payout ratio is currently 23.36%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ZBH. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. BTIG Research raised their price target on Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, October 13th. UBS Group lifted their target price on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research note on Friday, August 8th. Raymond James Financial lifted their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Evercore ISI cut their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $111.94.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.